Bortezomib (Velcade) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with Lymphoid Malignancies.

Trial Profile

Bortezomib (Velcade) and Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with Lymphoid Malignancies.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Bortezomib (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
  • Indications Lymphoproliferative disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 01 Aug 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 13 Jul 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Feb 2017 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top